Beyond behavioral improvements, Dihexa demonstrated potent synaptogenic activity
The primary end point was DMFS.[16][Level of evidence B1] At a median follow-up of 35.5 months, there was no difference in DMFS between patients randomly assigned to undergo observation (77%
Risk factors include male biological sex (boys are born with clubfoot twice as often as girls), genetic syndromes, neuromuscular disorders, birth defects and a breach birth
VK2735 is being developed as both an injectable and an oral treatment
Xingye D, Wenhao HZ, Qing Z, Wei W, Gaoren W, Jiaxiang G, Xiaobin B, Yunqing G, Xuefeng Z, Jiaye J, Yaozeng G
Work with a Healthcare Professional Regularly check in with your healthcare provider or a registered dietitian